ABSTRACT
Background Previous evidence indicates associations between the female reproductive tract microbiome composition and reproductive outcome in infertile patients undergoing assisted reproduction. We aimed to determine whether the endometrial microbiota composition is associated with reproductive outcomes of live birth, biochemical pregnancy, clinical miscarriage, or no pregnancy.
Methods Here we present a multicentre prospective observational study using 16S rRNA gene sequencing to analyse endometrial fluid and biopsy samples before embryo transfer in a cohort of 342 infertile patients asymptomatic for infection undergoing assisted reproductive treatments.
Results A dysbiotic endometrial microbiota profile composed of Atopobium, Bifidobacterium, Chryseobacterium, Gardnerella, Haemophilus, Klebsiella, Neisseria, Staphylococcus and Streptococcus was associated with unsuccessful outcomes. In contrast, Lactobacillus was consistently enriched in patients with live birth outcomes.
Conclusions Our findings indicate that endometrial microbiota composition before embryo transfer is a useful biomarker to predict reproductive outcome, offering an opportunity to further improve diagnosis and treatment strategies.
Competing Interest Statement
IM, DPV, MGM, DB, CG, DV, are partially employed by Igenomix R&D. CS is founder and head of the scientific advisory board of Igenomix. The rest of the authors declare that they have no competing interests.
Funding Statement
This study was supported by the Igenomix Foundation. IGG was supported by a Formacion de Profesorado Universitario grant (FPU15/01923) from the Spanish Ministry of Education. DB is supported by Torres-Quevedo grant (PTQ-16-08454) from the Spanish Ministry of Economy and Competitiveness. FV was supported by the Miguel Servet Program Type II of ISCIII (CPII18/00020) and the FIS project (PI18/00957). CS was supported by the Spanish Government MINECO/FEDER (grant RTI2018-094946-B-I00), the Valencian Innovation Council (ref. PROMETEO/2018/161) and the European Union Horizon 2020 Framework Programme for Research and Innovation under grant agreement number 874867.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the corresponding local Ethics Committees to the protocol with reference IGX1-MIC-CS-17-05 as follows: Western Institutional Review Board (IVF-Florida, USA, study code 1176556, July 17, 2017; RMA Connecticut, USA, study code 1177331, July 31, 2017; Dominion Fertility, USA, study code 1176555, July 22, 2017; Missouri Center for Reproductive Medicine, USA, study code 1179405, October 10, 2017; Pacific Centre for Reproductive Medicine, Canada, study code 1179667, December 13, 2017); Comite de Etica de la Investigacion con Medicamentos del Hospital Universitario de la Princesa (ProcreaTec, Spain, register number 3133, July 13, 2017); Comite de Etica de la Investigacion Costa del Sol (Clinica Fertia, Spain, code 006_jun17_PI-ERA-Microbioma, June 29, 2017); Comite de Bioetica del Instituto de Investigaciones Clinicas Rosario (Gestanza Medicina Reproductiva, Argentina, March 27, 2018); Comite de Etica en Investigacion Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno (Pregna Medicina Reproductiva, Argentina, October 13, 2017); Human Medical Research Ethics Committee (HMREC) for Private Healthcare and Research Centres Malaysia (Alpha IVF & Womens Specialists Centre, Malaysia, October 3, 2017); Oak Clinic Groups Ethics Committee (Oak Clinic Sumiyoshi, Japan, May 29, 2017); Comite de Etica en Investigacion New Hope Fertility Center (New Hope Fertility Center, Mexico, Register number RA-2017-04, June 9, 2017); Uskudar Universitesi Girisimsel Olamayan Arastirmalar Etik Kurulum (Bahceci Group, Turkey, January 25, 2018). All participants provided written informed consent. Data were monitored by clinical research associates through on-site and/or remote visits, and the database was properly curated by the data manager.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw data from this study is deposited at the Sequence Read Archive (accession code PRJNA691300) and will be publicly available upon acceptance of the manuscript.
